Clinical Trial Update: Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating MMFS-202-302 for cognitive enhancement in schizophrenia and schizoaffective disorder has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• MMFS-202-302

Snippet

Sponsor: Northwestern University | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: COMPLETED | Results posted: 2025-06-22